Evolus, Inc. — Major Shareholding Notification 2020

Jan 17, 2020

SC 13G/A 1 13g010820_sc13gz.htm SCHEDULE 13G/A Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2019 [PPXAC8S3T1P2VHL11E9Z]. www.edgarsuite.com Schedule 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

Evolus, Inc.
(Name of Issuer)
Common Stock, $0.00001 par value per share
(Title of Class of Securities)
30052C107
(CUSIP Number)
January 8, 2020
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[ ] Rule 13d-1(c)

[X] Rule 13d-1(d)

• The remainder of this cover page shall be filled out for a reporting person’s filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 30052C107 13G Page 2 of 5 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) AEON Biopharma, Inc. – (45-4777018)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3	SEC USE ONLY
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 0
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
12	TYPE OF REPORTING PERSON CO

CUSIP No. 30052C107 13G Page 3 of 5 Pages

Item 1(a)	Name of Issuer:
	Evolus, Inc.
Item 1(b)	Address of Issuer’s Principal Executive Offices:
	520 Newport Center Drive, Suite 1200 Newport Beach, California 92660
Item 2(a)	Name of Person Filing:
	AEON Biopharma, Inc. (f.k.a. Alphaeon Corporation) -- 45-4777018
Item 2(b)	Address of Principal Business Office or, If None, Residence
	AEON Biopharma, Inc. 4040 MacArthur Boulevard, Suite 310 Newport Beach, CA 92660
Item 2(c)	Citizenship:
	Delaware, USA
Item 2(d)	Title of Class of Securities:
	Common Stock, par value $0.00001 per share
Item 2(e)	CUSIP Number:
	30052C107
Item 3.	If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	Not Applicable.

CUSIP No. 30052C107 13G Page 4 of 5 Pages

Item 4.	Ownership
	(a) Amount beneficially owned: 0
	(b) Percent of Class: 0.0%
	(c) Number of shares as to which AEON Biopharma, Inc. has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒
Item 6.	Ownership of More Than Five Percent on Behalf of Another Person
	Not applicable.
Item 7.	Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
	Not applicable.
Item 8.	Identification and Classification of Members of the Group
	Not applicable.
Item 9.	Notice of Dissolution of Group
	Not applicable.
Item 10.	Certifications
	Not applicable.

CUSIP No. 30052C107 13G Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 17, 2020
By:	/s/ Vikram Malik
	Vikram Malik, Acting President